A sponsor (in this case Anavex) has to file an New Drug Application (NDA) with the FDA before the agency will consider whether to approve a drug for use in the U.S. While I respect your concern for dying patients, your anger toward the FDA is misplaced. If not for the slow pace of clinical development and lack of focus at Anavex, I believe an NDA could have been filed long ago.